% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:909507,
      author       = {Galldiks, Norbert and Langen, Karl-Josef and Albert,
                      Nathalie L and Law, Ian and Kim, Michelle M and
                      Villanueva-Meyer, Javier E and Soffietti, Riccardo and Wen,
                      Patrick Y and Weller, Michael and Tonn, Joerg C},
      title        = {{I}nvestigational {PET} tracers in
                      neuro-oncology—{W}hat’s on the horizon? {A} report of
                      the {PET}/{RANO} group},
      journal      = {Neuro-Oncology},
      volume       = {24},
      number       = {11},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2022-03213},
      pages        = {1815–1826},
      year         = {2022},
      abstract     = {Many studies in patients with brain tumors evaluating
                      innovative PET tracers have been published in recent years,
                      and the initial results are promising. Here, the Response
                      Assessment in Neuro-Oncology (RANO) PET working group
                      provides an overview of the literature on novel
                      investigational PET tracers for brain tumor patients.
                      Furthermore, newer indications of more established PET
                      tracers for the evaluation of glucose metabolism, amino acid
                      transport, hypoxia, cell proliferation, and others are also
                      discussed. Based on the preliminary findings, these novel
                      investigational PET tracers should be further evaluated
                      considering their promising potential. In particular, novel
                      PET probes for imaging of translocator protein and
                      somatostatin receptor overexpression as well as for immune
                      system reactions appear to be of additional clinical value
                      for tumor delineation and therapy monitoring. Progress in
                      developing these radiotracers may contribute to improving
                      brain tumor diagnostics and advancing clinical translational
                      research.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {35674736},
      UT           = {WOS:000807656300001},
      doi          = {10.1093/neuonc/noac131},
      url          = {https://juser.fz-juelich.de/record/909507},
}